Biogen Strategic Partnerships

Service · Consulting & advisory by Biogen

Transforming breakthrough science into global commercial success through strategic collaboration.

Biogen Strategic Partnerships provides biotechnology companies and researchers with global pharmaceutical resources and expertise to commercialize breakthrough science. It offers flexible deal structures, including equity investments, across neuroscience, immunology, and rare diseases.

Languages
English

Category: Drug Discovery

Industries served
Biotechnology, Pharmaceuticals, Research Institutions
Company Legacy
Nearly 50 years
Core Focus Areas
Neuroscience, Immunology, Nephrology, Rare Diseases
Rare Disease Prevalence Target
1-9/100,000 or greater
Investment Arm
Biogen New Ventures
Primary Modalities
ASOs, Small Molecules, Large Molecules, Biologics
  • Nearly 50-year legacy in complex diseases
  • Access to global pharma resources with biotech agility
  • Equity investments available via Biogen New Ventures
  • Focus on Neuroscience, Immunology, and Rare Diseases

Overview

Biogen Strategic Partnerships is a collaborative service for biotechnology companies and research institutions seeking to transform scientific discoveries into global commercial successes. Biogen leverages a nearly 50-year legacy in tackling complex diseases, combining the agility of a biotech firm with the resources of a global pharmaceutical leader. The program focuses on core therapeutic areas including Neuroscience, Immunology, Nephrology, and Rare Diseases. Partners gain access to Biogen's global commercialization capabilities and dedicated organizational structures. The service offers diverse deal structures, including potential equity investments through Biogen New Ventures. Every partnership is treated as a core part of Biogen's business, receiving personalized attention from senior leadership.

Therapeutic Areas of Opportunity

  • Neuroscience Focus: Biogen seeks partnerships for neurodegenerative, neuromuscular, and neurodevelopmental diseases including Alzheimer’s, Parkinson’s, and Huntington’s disease.
  • Immunology Focus: The company targets next-generation immune-mediated therapies for Lupus, Sjogren’s disease, Grave’s disease, and Myasthenia Gravis.
  • Nephrology Focus: Biogen advances investigational, immune-targeted therapies for kidney diseases such as IgAN, PMN, and Alport Syndrome.
  • Rare Diseases Focus: The program applies a proven commercial model to rare cardiology, hematology, and metabolic diseases with prevalence of 1-9/100,000 or greater.

Modalities and Platforms

  • Established Modalities: Biogen builds on expertise with antisense oligonucleotides (ASOs), small molecules, large molecules, and biologics.
  • Nucleic Acid Therapeutics: The company explores nucleic acid therapeutics including siRNA and mRNA.
  • Chemistry Technologies: Partnerships include traditional and next-generation chemistry technologies such as covalent, proximity-induced, and AI-enabled methods.
  • Platform Technologies: Biogen seeks platform technologies that enhance its pipeline, including delivery technologies and engineered biologics.

Strategic Collaboration Model

  • Diverse Deal Structures: Biogen offers a variety of partnership structures uniquely tailored for each opportunity.
  • Equity Investments: The program now includes potential equity investments through Biogen New Ventures.
  • Senior Leadership Engagement: Every external partnership receives hands-on, personalized attention from Biogen's senior leaders.
  • Dedicated Resources: Biogen dedicates specific organizational structures and capital to support each program at scale.

What's included

  • Research and development collaboration, global commercialization, equity investment, and distribution support

Published results

  • Transformation of breakthrough science into global commercial success

Use cases

  • Biotech startups collaborate with Biogen to access global commercialization resources for neurodegenerative disease treatments.
  • Research institutions partner with Biogen to advance investigational immune-targeted therapies for rare kidney diseases.
  • Early-stage companies receive equity investments through Biogen New Ventures to accelerate the development of nucleic acid therapeutics.
  • Established firms leverage Biogen's distribution network to reach patients in over 60 additional markets worldwide.

Specifications

Engagement model
Strategic partnership, including equity investments through Biogen New Ventures
Industries served
Biotechnology, Pharmaceuticals, Research Institutions
Company Legacy
Nearly 50 years
Core Focus Areas
Neuroscience, Immunology, Nephrology, Rare Diseases
Rare Disease Prevalence Target
1-9/100,000 or greater
Investment Arm
Biogen New Ventures
Primary Modalities
ASOs, Small Molecules, Large Molecules, Biologics
Advanced Modalities
siRNA, mRNA, AI-enabled chemistry

How it works

  1. Initial Connection: Potential partners reach out to Biogen via the dedicated partnering email to initiate discussions regarding scientific or commercial opportunities.
  2. Opportunity Assessment: Biogen evaluates the opportunity based on its core focus areas, including Neuroscience, Immunology, Nephrology, and Rare Diseases.
  3. Structure Tailoring: The teams work to define a unique partnership structure, which may include R&D collaboration, distribution agreements, or equity investments.
  4. Program Execution: Once established, the partnership receives dedicated capital, organizational structures, and personalized attention from Biogen senior leadership.

FAQ

What therapeutic areas is Biogen interested in?

Biogen focuses on Neuroscience (including Alzheimer's and Parkinson's), Immunology (Lupus, Sjogren's), Nephrology (kidney diseases), and Rare Diseases (cardiology, hematology, metabolic).

How does Biogen support its partners?

Biogen combines biotech agility with global pharma capabilities, offering partners hands-on, personalized attention from senior leaders and dedicated resources for every program.

What modalities and platforms are of interest to Biogen?

Biogen is interested in ASOs, small and large molecules, biologics, nucleic acid therapeutics (siRNA, mRNA), and next-generation chemistry technologies like AI-enabled platforms.

Added by AntSpace from public sources (biogen.com).

Related

More services by Biogen